Video

Implementing the Joint Commission's Infectious Disease Requirements

Lisa Dumkow, PharmD, BCIDP, discusses some techniques for successfully implementing the Joint Commission's newest requirements. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas.

Lisa Dumkow, PharmD, BCIDP, discusses some techniques for successfully implementing the Joint Commission's newest requirements. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas.

Lisa Dumkow, PharmD, BCIDP: The Joint Comission has 5 different elements of performance that they are expecting to be implemented, and these are modeled after the CDC’s 4 core elements of performance for outpatient stewardship programs. The first and foremost is having a leadership commitment, so be that an ID pharmacist, physician, or an outpatient ambulatory care pharmacist or physician, someone needs to be responsible for leading that charge in the outpatient setting. Other performance standards have to do with knowing your data, being able to share that with prescribers, and then giving that feedback to them to make changes. So, having that annual goal set based on your data as well.

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Cavan - stock.adobe.com
Image Credit: © utah51 - stock.adobe.com
Image Credit: © Rawpixel.com - stock.adobe.com